Table 4.
Contents of β-artemether and lumefantrine in fixed dose combination (FDC) products (n=6)
|
FDC samples |
Batch/Lot No. |
Content (%) ± S.D. |
|
|---|---|---|---|
| β-artemether | Lumefantrine | ||
| Artemine® tablets |
A |
103.2 ± 1.5 |
101.5 ± 0.9 |
| |
B |
102.2 ± 1.7 |
101.3 ± 0.5 |
| Coartem® tablets |
A |
98.2 ± 0.9 |
97.92 ± 0.7 |
| |
B |
99.2 ± 1.5 |
98.8 ± 0.7 |
| Co-Artesiane powder for oral suspension | A |
100.9 ± 1.9 |
101.4 ± 0.9 |
| B |
99.7 ± 1.6 |
102.0 ± 0.8 |
|
| C | 101.1 ± 1.3 | 100.8 ± 0.8 | |
S.D. = standard deviation.